Considerable efforts have recently been made to discover new analgesic and antiinflammatory agents with increased efficacy and improved side effect profiles. In this context, the compounds obtained from medicinal plants have been extensively studied.
3Ј), 3.17 (2H, dd, Jϭ16.0, 9.2 Hz, H-3), 3.29 (2H, m, H-1Љ), 4 .74 (1H, t, Jϭ9.2 Hz, H-2), 5.12 (1H, t, Jϭ7.2 Hz, H-4Ј), 5.28 (1H, t, Jϭ7.2 Hz, H2Љ), 7.75 (2H, s, H-4, H-6). 13 C-NMR (CDCl 3 , 75.5 MHz) d: 17.7 (C-8Ј), 17.9 (C-5Љ), 22 .0 (C-3Ј), 22 .6 (C-7Ј), 25 .6 (C-4Љ), 25.7 (C-6Ј), 28 .3 (C-1Љ), 29.9 (C-3), 37.1 (C-2Ј), 73.8 (C-1Ј), 89.6 (C-2), 121.4 (C-2Љ), 121.8 (C-5), 123.1 (C-3a), 124.0 (C-4Ј), 125.0 (C-6), 127.2 (C-7), 131.4 (C-4), 132.2 (C-5Ј), 133.2 (C-3Љ), 162.4 (C-7a), 171.7 (C8).
Animals The experiments were conducted using male Swiss mice (25-35 g ), housed at 22Ϯ2°C under a 12-h light/dark cycle (lights switched on at 6:00) and with access to food and water ad libitum. The animals were acclimatized to the laboratory for at least 1 h before testing and were used only once throughout the experiments. The experiments were performed after approval of the protocol by the Institutional Ethics Committee of UNIVALI (474/2004-CEP/UNIVALI) and were carried out in accordance with the current guidelines for the care of laboratory animals and the ethical guidelines for investigations of experimental pain in conscious animals.
9) The number of animals and intensity of the noxious stimuli used were the minimum necessary to demonstrate the consistent effects of the drug treatments.
Evaluation of the Possible Mechanism of Action of AMB To address some of the mechanisms by which AMB causes antinociception, as detected in previous investigations, 8 ) the acetic acid model was chosen. 10) This model has been described as a typical model of inflammatory pain. This model has long been used as a screening tool for assessment of analgesic or anti-inflammatory properties of new agents. 10) In this model, the animals were pre-treated with different drugs. The doses of the drugs used were selected based on the literature data and on previous results of our laboratory. 8, 11, 12) The possible participation of several systems in antinociception elicited by AMB (60 mg/kg, intraperitonially (i.p.)) in mice was analyzed based on the reversion of its antinociceptive effects. 11, 12) Participation of a a-Adrenergic Receptors To assess the possible participation of a-adrenergic receptors, the animals were pretreated with yohimbine (0.2 mg/kg, i.p.) or prazosin (0.2 mg/kg, i.p.) 15 min before administration of AMB (60 mg/kg, i.p.) phenylephrine (10 mg/kg, i.p.) or clonidine (0.2 mg/kg, i.p.). The pain response caused by injection of acetic acid (0.6%) was analyzed 30 min after the administration of AMB or agonists. Other groups of animals received only AMB (60 mg/kg, i.p.), phenylephrine (10 mg/kg, i.p.), clonidine (0.2 mg/kg, i.p.) or the vehicle (NaCl 0.9 w/v %) 30 min before acetic acid injection.
Participation of Nitric Oxide Pathway In separate experiments, we investigated the possible participation of the nitric oxide L-arginine pathway on the analgesic effect caused by AMB. To this end, the animals were pre-treated with Larginine (600 mg/kg, i.p.) and after 15 min they received the AMB (60 mg/kg, i.p.), NG-nitro-L-arginine (L-NOARG, 75 mg/kg, i.p.). The pain caused by acetic acid injection was analyzed 30 min after treatment of the animals with the AMB or with L-NOARG. The other groups received AMB or the vehicle (NaCl 0.9 w/v %) 30 min before acetic acid injection.
Participation of Serotonin to the Analgesic Profile To assess the possible contribution of serotonin to the analgesic profile of AMB, the animals received p-chlorophenylalanine (PCPA) (100 mg/kg, i.p.) once a day for 4 consecutive days, ondansetron (0.3 mg/kg), 1-(2-methoxyphenyl)-4-(4-phthalimidobutyl)piperazine (NAN) 190 (0.5 mg/kg, i.p.) or ketanserin (1.0 mg/kg, i.p.) 15 min before administration of AMB (60 mg/kg, i.p.). The pain response caused by of acetic acid injection was analyzed 30 min after administration of AMB. Another group of mice was treated with vehicle (NaCl 0.9 w/v %) 30 min before acetic acid injection.
Participation of Gamma Aminobutyric Acid (GABA)-ergic System In the same model, the possible participation of the GABAergic system on the analgesic effect caused by AMB was investigated. With this aim, the animals were pretreated with bicuculline (1.0 mg/kg, i.p.) or phaclofen (2.0 mg/kg, i.p.) and after 15 min, they received AMB (60 mg/kg, i.p.), muscimol (2.0 mg/kg, i.p.) or baclofen (2.0 mg/kg, i.p.). The pain caused by acetic acid injection was analyzed 30 min after treatment of the animals with AMB, muscimol or baclofen. The other groups received AMB or the vehicle (NaCl 0.9 w/v %) 30 min before acetic acid injection.
Participation of Dopaminergic and Cholinergic Systems The participation of the dopaminergic and cholinergic systems was also investigated. For this purpose, the animals were pre-treated with haloperidol (0.2 mg/kg, i.p.) and after 15 min, they received AMB (60 mg/kg, i.p.) or apomorphine (1.0 mg/kg i.p.). Another group was pre-treated with atropine (10 mg/kg, i.p.) and after 15 min, they received AMB (60 mg/kg, i.p.) or acetylcholine (1.0 mg/kg i.p.). The pain caused by acetic acid injection was analyzed 30 min after treatment of the animals with AMB apomorphine and acetylcholine. The other groups received AMB or the vehicle (NaCl 0.9 w/v %) 30 min before acetic acid injection.
Participation of Opioid System To investigate the possible participation of the opioid system on the antinociceptive effect of AMB, the mice were pre-treated with naloxone (1.0 mg/kg, i.p.), and after 15 min, the animals received an injection of AMB (60 mg/kg, i.p.), morphine (5 mg/kg, s.c.) or vehicle (NaCl 0.9 w/v %). The other groups were pretreated with vehicle (saline, 10 ml/kg), and after 15 min received AMB, morphine or vehicle, 30 min before acetic acid injection.
Participation of Endogenous Glucocorticosteroids Finally, in the other experiments, we investigated the possible participation of the endogenous glucocorticosteroids on the analgesic effect caused by AMB. As described by WillainFilho and co-workers, 11) the animals were bilaterally adrenalectomized through dorsal incision, and after 2 weeks they were pretreated with vehicle (NaCl 0.9 w/v %), 30 min before acetic acid injection. Adrenalectomy (ADX) was carried out under anesthesia, and both adrenal glands were removed. Sham-operated (SHO) animals were used as control. The ADX mice were given 0.9 w/v % NaCl solution (saline) to drink, instead of water.
Statistical Analysis The results are presented as meanϮS.E.M. The statistical significance of differences between groups was performed by ANOVA followed by Tukey test. p-values less than 0.05 ( pϽ0.05) were considered as indicative of significance.
RESULTS
Participation of a a-Adrenergic Receptors Treatment of the animals with prazosin (0.2 mg/kg, i.p.) or yohimbine (0.2 mg/kg, i.p.), 15 min before hand, significantly reversed the antinociception caused by phenylephrine (10 mg/kg, i.p.), and clonidine (0.2 mg/kg, i.p.), respectively (Fig. 2) . The same treatment with prazosin and yohimbine significantly antagonized the antinociceptive action caused by AMB against acetic acid-induced pain.
Participation of Nitric Oxide Pathway
The results presented in Fig. 3 show that mice pre-treatment with nitric oxide precursor L-arginine (600 mg/kg, i.p.), given 15 min prior to testing, but not with D-arginine (600 mg/kg, i.p.), significantly prevented (pϽ0.05) the antinociception caused by L-NOARG (75 mg/kg, i.p.) and by AMB (60 mg/kg, i.p.) when analyzed against acetic acid-induced abdominal constrictions.
Participation of Serotonin to the Analgesic Profile Pre-treatment of the animals with PCPA for 4 consecutive days produced significant inhibition of the antinociception caused by AMB (60 mg/kg, i.p.) against acetic acid-induced pain (Fig. 4A ). In addition, the antinociception caused by AMB was significantly attenuated by pre-treatment of mice with NAN 190 (0.5 mg/kg, i.p.). In contrast, ketanserin (1.0 mg/kg, i.p.) or ondansetron (0.3 mg/kg, i.p.) 15 min beforehand did not reverse the antinociception caused by AMB (60 mg/kg, i.p.) against acetic acid-induced pain (Fig. 4B) . Each column represents the mean of six to eight mice and the error bars indicate the S.E.M. The symbols denote significance levels * * pϽ0.01 compared to control group; ## pϽ0.01 compared to phenylephrine, clonidine and AMB without yohimbine or prazosin group (ANOVA followed by Tukey test). Each column represents the mean of six to eight mice and the error bars indicate the S.E.M. The symbols denote significance levels * * * pϽ0.001 compared to control group; # pϽ0.05 compared to muscimol, baclofen and AMB without bicuculline or phaclofen group (one-way ANOVA followed by Tukey test). mg/kg, i.p.) ( Fig. 5 ) but had no effect on the antinociceptive action caused by AMB when analyzed against acetic acidinduced abdominal constrictions.
Participation of GABAergic System
Participation of Dopaminergic and Cholinergic Systems The effects of AMB on dopaminergic and cholinergic pathways are described in Fig. 6 . Systemic treatment of the mice with atropine (10 mg/kg, i.p.) given 15 min before, significantly reversed the antinociception caused by acetylcholine and AMB (60 mg/kg, i.p.) when assessed in acetic acid induced abdominal constrictions (Fig. 6A) . Previous treatment of the animals with haloperidol, (0.2 mg/kg, i.p.) under conditions in which this drug almost completely reversed the antinociception caused by apomorphine (1.0 mg/kg, i.p.), failed in to revert the antinociception caused by AMB (Fig. 6B) .
Participation of Opioid System
The results presented in Fig. 7 show that pre-treatment of the mice with naloxone (5 mg/kg, i.p.), given 15 min beforehand, reversed the antinociception caused by morphine (5 mg/kg, s.c.) against acetic acid-induced pain, without affecting the antinociception caused by AMB (60 mg/kg, i.p.).
Participation of Endogenous Glucocorticosteroids Finally, the results also demonstrate that bilateral adrenalectomy of animals, performed 1 week prior to the experiments, significantly reversed the antinociception caused by AMB in this same model (Fig. 8) .
DISCUSSION
Previous studies demonstrate that systemic administration (i.p. or p.o.) of the AMB at doses that do not produce any observed motor dysfunction, caused inhibition of acetic acidinduced visceral nociceptive response in mice. It was also observed that administration this compound caused significant inhibition of glutamate, formalin and capsaicin-induced nociception and anti-hyperalgesic effect on the intraplantar injection of bradykinin, epinephrine, capsaicin and carrageenan in rats. In addition, was also observed that its antinociceptive effect remained significant up to 6 h after administration. 8) In the present study, we attempted to further characterize some of the mechanisms through which AMB exerts its antinociceptive action.
Pain sensation can be divided into four components: transduction, transmission, modulation and perception. Several studies have shown that systems of neurotransmitters such as oxidonitrergic, GABAergic, glutamatergic, opioid, cholinergic, serotonergic, adrenergic, dopaminergic cannabinoids and other may act in different ways during the painful process, interfering in one of its components what makes the pain a very complex phenomenon. 13) A natural or synthetic substance with analgesic properties can then interfere with one of these four components to produce analgesia. Its mecha- Each column represents the mean six to eight mice and the error bars indicate the S.E.M. The symbols denote significance levels * * * pϽ0.001 compared to control group; # pϽ0.05 compared to morphine and AMB without naloxone group (one-way ANOVA followed by Tukey test). nism of action may involve neurotransmitter systems such as those listed above. The L-arginine/nitric oxide pathways are involved in several models of nociception. 11, 14) Then we demonstrated across the results that the L-arginine-nitric oxide pathway is likely to be involved in antinociception caused by AMB. This conclusion is drawn from the fact that pre-treatment of the mice with the nitric oxide synthase (NOS) substrate L-arginine, at a dose that produced no significant effect on acetic acid-induced pain, significantly reversed the antinociception caused by both AMB and L-NOARG (a known nitric oxide inhibitor). In marked contrast, pre-treatment of the animals with the inactive isomero L-arginine, D-arginine, had no significant effect against both AMB and L-NOARG-induced antinociception. 11, 12) Among the neurotransmitter systems involved in pain, the opioid system is one of the most important. The four components of pain, this system participates in both the perception of modulation. 15) Moreover not yet found an analgesic agent whose therapeutic effect is the same as that morphine, but that does not have side effects. Our data demonstrate that the activation of the opioid naloxone sensitive pathway is probably not involved in the antinociception produced by AMB because naloxone significantly reversed morphine, but not AMB antinociception, in the acetic acid test. These observations are in agreement with previous findings in our laboratory 8) that AMB was ineffective in the hot-plate and tail-flick tests, models in which drugs with morphine-like effect are effective.
The results indicate that the antinociception caused by AMB may be also be mediated by the activation of the adrenergic system. Treatment with prazosin and yohimbine significantly antagonized the antinociceptive action caused by AMB, and this effect may be mediated by the activation of the adrenergic system. Umeda and co-workers 16) demonstrate that nonsynaptic release of norepinephrine from rat spinal cord slices is modulated via presynaptic a 2A -adrenergic auto receptors. It was observed that the a 2A -adrenoreceptor agonist clonidine inhibited this pathway, whereas yohimbine (a non subtype selective a 2A antagonist) enhanced the release of norepinephrine in response to neuronal stimulation. 17) It is possible that the a2-adrenoceptor agonist exerts antinociceptive effects, at least partially, through a presynaptic modulation of primary afferent fibers that convey the nociceptive messages to the spinal cord. In our experiment also prazosin administration attenuated the antinociceptive effect of AMB, demonstrating that this effect may be mediated also by the activation of a1-adrenoreceptor. The effects of a1-adrenoreceptors in analgesia has been contradictory and depend on the type of pain assessed, the type of species and the animal model used in the study. Cutaneous a1-adrenoceptor stimulation augments hyperalgesia and nociceptive discharge in animal models of neuropathic pain and inflammation, 18) and generates pain and hyperalgesia in humans. 19) On the other hand the microinjection of the a1-adrenoceptor antagonist, prazosin, into the nucleus raphe magnus, a brain nucleus involved in nociceptive processing, produces antinociception similar to the a2-adrenoceptor agonist clonidine.
20)
The cholinergic system is probably involved in the AMB action, this was evidenced by the fact that atropine, a non-selective cholinergic receptor antagonist, inhibited the antinociceptive effect of AMB. Furthermore, it has been reported that both systemically and intrathecally administered cholinergic agonists produce antinociception, while cholinergic antagonists decrease the pain threshold, 21) but the mechanism and the site of action of these substances are not known.
In spite of the numerous studies showing the importance of the central serotonergic pathways in pain regulation, several points require clarification. 22) For instance, the exact nature of the receptors involved in the 5-HT-induced modulation of pain in the spinal cord and in other regions of the central nervous system remains to be elucidated. In relation to serotonergic receptors involved in pain there is no very clear. Although additional subtypes (5-HT6 and 5-HT7) certainly exist, 23) studies have revealed the presence of at least four types of 5-HT receptors in the spinal cord (5-HT1, 5-HT2, 5-HT3 and 5-HT4) with several subtypes. 24, 25) The use of relatively selective agonists and antagonists at the recently described 5-HT receptor subtypes has brought to light a complex picture of the roles of these receptors in that spinal administration can produce both pro-and antinociceptive effects. In the tail-flick test, intrathecally administered 5-HT1 A antagonists do not alter 26) or produce a dose-related blockade 27 ) of 5-HT-induced antinociception. Intrathecal (i.t.) administration of 5-HT1 A agonists has been reported to facilitate, 28) to inhibit 27) or to not modify pain reactions. 29) A similar degree of controversy exists concerning the possible role played by the 5-HT2 and 5-HT3 receptors. Activation of the 5-HT2 receptors has been reported to facilitate 30) or to inhibit 31) the transmission of the nociceptive impulse. In the case of 5-HT3 receptors, 32) showed an antinociceptive effect of spinal 5-HT3 receptor activation, whereas some studies have failed to demonstrate 5-HT3 receptor-mediated control of nociception 27) and pronociceptive actions have been described. 33) The role of 5-HT4 receptors in nociceptive transmission is not clearly defined, however, 5-HT4 receptor agonists have been shown to exert potent antinociceptive activity through a central mechanism. 34) On the other hand, antagonism of peripheral 5-HT4 receptors reduces visceral and cutaneous pain in mice. 35) The results of the present study show that AMB produces antinociception that appears to be mediated the serotonergic system, especially through the stimulation of 5-HT1 receptors. This assertion is supported by the demonstration that (1) depletion of endogenous serotonin with the tryptophan hydroxylase inhibitor PCPA, at a dose known to decrease the cortical content of serotonin and to significantly reverse morphine antinociception, 11, 12) largely antagonized the antinociceptive action of the AMB; (2) selective antagonist 5-HT1 A receptors, namely NAN-190, consistently reversed the antinociception caused by systemic administration of the AMB when analyzed against acetic acid-induced pain; in marked contrast, selective antagonists of 5-HT2 A and 5-HT3 receptors, namely ketanserin and ondansetron, respectively, do not appear to account, to any large extent, for the antinociceptive action of the AMB. Furthermore, several studies have demonstrated the involvement of 5-HT1 A receptors in the mechanism of action of many classes of antidepressant drugs, including tricycles, SSRIs (selective serotonin reuptake inhibitors) and MAOis (monoamine oxidase inhibitors. 36 ) Thus, our data clearly indicate that in the model of visceral pain, the antinociceptive action of AMB was reduced by selective 5-HT1 A receptor antagonist, which suggest that 5-HT1 A receptor stimulation (but no 5-HT2A and 5-HT3 receptors) by AMB produces analgesic-like effect. Several works have reported the implication of GABAergic pathway as a system also implicated in endogenous modulation of pain. 37, 38) The modulation of ionotropic GABA receptors (GABA-gated Cl(Ϫ) channels) by a group of natural products such as flavonoids, was studied in electrophysiological experiments. Quercetin, apigenin, morin, chrysin and flavone inhibited ionic currents mediated by alpha(1) beta(1) gamma(2s) GABA(A) and GABA(C) receptors expressed in Xenopus laevis oocytes in the micromolar range. 39) Baclofen, a derivative of GABA, is a potent GABA B receptor agonist, which is clinically used for the treatment of spasticity, many types of neuropathic pain, but also induces analgesia in certain animal models of pain. [40] [41] [42] [43] In this study and others realized in our laboratories 11, 12, 44) the results confirm that baclofen and muscimol markedly antagonizes acetic acidinduced nociception. In contrast, GABA A or the GABA B antagonists bicuculline or phaclofen did not reversed the antinociceptive effect of AMB, demonstrating that the antinociceptive effect of this compound does not involve the action of the GABAergic pathways.
The modulation of spinal dopaminergic transmission, although it is known that both inputs and sustained acute noxious stimuli accelerate dopamine turnover in the dorsal horn, suggesting an enhancement in the activity of the descending dopaminergic pathways. Dopaminergic mechanisms may play a part in the accompanying antinociception. 45, 46) In diseases characterized by a lack of dopaminergic neurotransmission, such as Parkinson's disease, pain is common and can precede the diagnosis of the disease. 47) Recently, Slaoui et al. 48) showed that levodopa increased heat and cold pain thresholds and heat pain tolerance in patients with Parkinson's disease. This suggests that dopaminergic drugs could have an analgesic effect on Parkinson-related pain. In this study our results showed that haloperidol, administered systemically, did not revert the antinociceptive effect caused by AMB, suggesting that antinociception is not dependent on the dopaminergic system.
Despite the fact that the literature supports a strong link between pain, stress disorders, and limbic dysfunction, the mechanisms underlying the effects of pain on the hypothalamic-pituitary-adrenal (HPA) axis and limbic system are not understood. The type of pain most studied making this relationship is the chronic pain because chronic pain can be considered a form of chronic stress 49) and, exposure to stress activates the neuroendocrine HPA axis. Glucocorticoids play important roles in response to stressful stimuli, including pain. Several studies have reported that bilateral ADX intensifies dolorous reactions in animals. 50, 51) Zhang et al. 52) demonstrate that complete Freund's adjuvant (CFA) induced more intense hyperalgesia and up-expression of spinal preprodynorphin mRNA in ADX rats than in control rats, while both of these intensified reactions could be significantly suppressed by subcutaneous pretreatment with dexametazone. Khasar et al. 53) recently demonstrated that an important mechanism in generalized pain syndromes may be stress-induced coactivation of the hypothalamo-pituitary-adrenal and sympathoadrenal axes, causing a long-lasting alteration in the intracellular signaling pathways and enabling normally innocuous levels of immune mediators to produce chronic hyperalgesia.
In this study, the results interestingly demonstrate that the ADX of the animals also significantly modified the AMBinduced analgesic effect, which suggests that the antinociceptive effects of the compound depend on the endogenous release of glucocorticoids. These results may have a complementary relation with those obtained with AMB in adrenergic and serotonergic systems, since both pathways are important in the pathogenesis of painful procedures and pathogenesis of diseases related to stress.
In conclusion, these and previous results obtained in our laboratories provide convincing evidence indicating that AMB, a prenylated benzoic acid, occurring in Rapanea ferruginea, produces systemic antinociception when assessed in chemical models of nociception in mice, at doses that reveal no interference with locomotor activity. The results suggest that AMB itself may have potential therapeutic value for the development of new analgesic drugs, and the antinociception mechanism appears to involve an interaction with the a-adrenoceptors, and the serotonergic, oxidonitrergic and cholinergic systems. Its action is also modulated by the HPA axis.
